Cargando…

Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat(®) Soft Mist(™) Inhaler

Current guidelines for the management of chronic obstructive pulmonary disease (COPD) recommend the regular use of inhaled bronchodilator therapy in order to relieve symptoms and prevent exacerbations. A variety of inhaler devices are currently available to COPD patients, and the choice of device is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hodder, Richard, Price, David
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829861/ https://www.ncbi.nlm.nih.gov/pubmed/19888356

Ejemplares similares

Asthma patients prefer Respimat(®) Soft Mist™ Inhaler to Turbuhaler(®)
por: Hodder, Rick, et al.
Publicado: (2009)

Use of Respimat(®) Soft Mist™ Inhaler in COPD patients
por: Anderson, Paula
Publicado: (2006)

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(®) Soft Mist™ Inhaler in COPD
por: Hodder, Rick, et al.
Publicado: (2011)

The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
por: Iwanaga, Takashi, et al.
Publicado: (2019)

Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders
por: Dalby, Richard N, et al.
Publicado: (2011)

Reduced Environmental Impact of the Reusable Respimat(®) Soft Mist™ Inhaler Compared with Pressurised Metered-Dose Inhalers
por: Hänsel, Michaela, et al.
Publicado: (2019)

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
por: Kunz, Christina, et al.
Publicado: (2016)

Long-term safety of tiotropium delivered by Respimat(®) SoftMist™ Inhaler: patient selection and special considerations
por: Tan, Ching Kuo, et al.
Publicado: (2016)

Higher lung deposition with Respimat(®) Soft Mist(™) Inhaler than HFA-MDI in COPD patients with poor technique
por: Brand, Peter, et al.
Publicado: (2008)

A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old
por: Kamin, Wolfgang, et al.
Publicado: (2015)

Patient perceptions of the re-usable Respimat(®) Soft Mist™ inhaler in current users and those switching to the device: A real-world, non-interventional COPD study
por: Dreher, Michael, et al.
Publicado: (2021)

Clinical effectiveness of the Respimat(®) inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
por: Ram, Felix SF, et al.
Publicado: (2011)

A dose-ranging study of tiotropium delivered via Respimat(®) Soft Mist(TM) Inhaler or HandiHaler(®) in COPD patients
por: Caillaud, Denis, et al.
Publicado: (2007)

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®)
por: Dekhuijzen, Pieter Nicolaas Richard, et al.
Publicado: (2016)

Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices
por: Hira, Daiki, et al.
Publicado: (2018)

Technical Evaluation of Soft Mist Inhaler Use in Patients with Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study
por: Zhang, Wei, et al.
Publicado: (2020)

Reducing carbon footprint by switching to reusable soft-mist inhalers
por: Janson, Christer, et al.
Publicado: (2023)

In vitro dose comparison of Respimat(®) inhaler with dry powder inhalers for COPD maintenance therapy
por: Ciciliani, Anna-Maria, et al.
Publicado: (2017)

Inhaler usability of a pressurized metered dose inhaler and a soft mist inhaler in patients with COPD: A simulated-use study
por: Ding, Bo, et al.
Publicado: (2018)

Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis
por: Navaie, Maryam, et al.
Publicado: (2020)

Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat(®) Soft Mist(™) Inhaler: findings from two dose-ranging studies in healthy men
por: Feifel, Ulrich, et al.
Publicado: (2008)

Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch
por: Hanada, Soichiro, et al.
Publicado: (2015)

Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered‐Dose Inhaler
por: MacGregor, TR, et al.
Publicado: (2016)

Quantifying the importance of inhaler attributes corresponding to items in the patient satisfaction and preference questionnaire in patients using Combivent Respimat
por: Davis, Kimberly H., et al.
Publicado: (2017)

Effect of Tiotropium Soft Mist Inhalers on Dynamic Changes in Lung Mechanics of Patients with Chronic Obstructive Pulmonary Disease Receiving Mechanical Ventilation: A Prospective Pilot Study
por: Fu, Pin-Kuei, et al.
Publicado: (2020)

Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat(®) Inhaler in Patients with Chronic Obstructive Pulmonary Disease
por: Aalbers, René, et al.
Publicado: (2015)

A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
por: Dahl, Ronald, et al.
Publicado: (2016)

Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials
por: Singh, Sonal, et al.
Publicado: (2011)

Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting
por: Yawn, Barbara P, et al.
Publicado: (2012)

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease
por: Rau-Berger, Heike, et al.
Publicado: (2010)

Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers
por: Singer, David, et al.
Publicado: (2020)

Pharmacokinetic Study of Epinephrine Hydrofluoroalkane (Primatene MIST) Metered-Dose Inhaler
por: Kerwin, Edward M., et al.
Publicado: (2020)

Exploring General Practitioners’ Preferences and Experience with Respiratory Inhaler Devices
por: Cvetkovski, Biljana, et al.
Publicado: (2022)

Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment
por: Tervonen, Tommi, et al.
Publicado: (2020)

Errors in inhaler use related to devices and to inhalation technique among patients with chronic obstructive pulmonary disease in primary health care
por: Lindh, Annika, et al.
Publicado: (2019)

Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study
por: Dal Negro, Roberto W., et al.
Publicado: (2017)

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2018)

Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease
por: Janson, Christer
Publicado: (2020)

The future of inhalation therapy in chronic obstructive pulmonary disease
por: Cazzola, Mario, et al.
Publicado: (2022)

Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA(®) Dry Powder Inhaler
por: Prime, David, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qk4s6nrceep1dsal2npatimkci